secwatch.observer — SEC 8-K summary
======================================

Issuer:     Tonix Pharmaceuticals Holding Corp. (TNXP)
CIK:        0001430306
Form:       8-K
Filed at:   2025-08-15T23:59:59+00:00
Accession:  0001999371-25-011478
Event type: regulatory
Sentiment:  positive
Materiality: 0.90
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

FDA approves Tonix's Tonmya for fibromyalgia; first new therapy in over 15 years
--------------------------------------------------------------------------------

- Tonmya (cyclobenzaprine HCl sublingual tablets) approved for adults with fibromyalgia; Q4 2025 commercial launch expected.
- Approval based on two Phase 3 trials (~1,000 patients) showing significant pain reduction vs placebo at 14 weeks.
- Over 10 million U.S. adults affected; Tonmya is first-in-class non-opioid bedtime analgesic.
- Company to host webcast August 18 at 8:30 AM ET to discuss approval.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1430306/000199937125011478/0001999371-25-011478-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1430306/000199937125011478/tnxp_8k-081525.htm
  HTML page:      https://secwatch.observer/filing/0001999371-25-011478

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer